Context Therapeutics Inc. (CNTX)
NCM · Healthcare · Biotechnology
$0.35
-4.26%
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
Market Cap
$32.2M
Shares Outstanding
91.9M
Exchange
NCM
Currency
USD
About Context Therapeutics Inc.
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (10.6M) | (13.8M) | (9.3M) | (15.0M) |
| Net Income | (9.7M) | (13.0M) | (8.7M) | (14.6M) |
| Diluted EPS | $-0.10 | N/A | $-0.09 | $-0.15 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (14.9M) | (25.1M) | (29.9M) | (39.7M) |
| Net Income | (14.8M) | (24.0M) | (26.7M) | (36.1M) |
| Diluted EPS | $-0.93 | $-1.50 | $-0.46 | $-0.38 |